Results 61 to 70 of about 13,555 (204)

Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells

PLoS ONE, 2014
High level MYC expression is associated with almost all human cancers. JQ1, a chemical compound that inhibits MYC expression is therapeutically effective in preclinical animal models in midline carcinoma, and Burkitt's lymphoma (BL). Here we show that JQ1 does not inhibit MYC expression to a similar extent in all tumor cells. The BL cells showed a ∼90%
Fowler, Trent, Ghatak, Payel, Price, David H., Conaway, Ronald, Conaway, Joan, Chiang, Cheng-Ming, Shilatifard, Ali, Roy, Ananda L., Bradner, James E   +8 more
openaire   +6 more sources

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy [PDF]

Molecular Cancer Therapeutics, 2015
Abstract Genetically engineered mouse models of lung cancer have demonstrated an important role in understanding the function of novel lung cancer oncogenes and tumor-suppressor genes identified in genomic studies of human lung cancer. Furthermore, these models are important platforms for preclinical therapeutic studies.
Chunxiao, Xu, Kevin A, Buczkowski, Yanxi, Zhang, Hajime, Asahina, Ellen M, Beauchamp, Hideki, Terai, Yvonne Y, Li, Matthew, Meyerson, Kwok-Kin, Wong, Peter S, Hammerman   +9 more
openaire   +2 more sources

JQ1(+) treatment increases the MCV replication.

, 2012
A. JQ1(+) releases Brd4 from chromatin. C33A cells were treated with 300 nM JQ1(+), JQ1(−) or DMSO for 24 h. Cells were fixed and stained with Brd4 antibody and DAPI. B. JQ1(+) treatment increases the MCV replication.
Jianxin You (121729), Christopher B. Buck (121726), Jing Li (10611), Rachel M. Schowalter (121719), Xin Wang (91924), Jing Jiao (121723)   +5 more
core   +1 more source

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

eLife, 2017
In 2015, as part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Kandela et al., 2015) that described how we intended to replicate selected experiments from the paper "BET bromodomain inhibition as a therapeutic strategy
Fraser Aird, Irawati Kandela, Christine Mantis, Reproducibility Project: Cancer Biology   +3 more
doaj   +1 more source

AI‐Powered Framework for Evaluating Drug Efficacy for Three‐Dimensional In Vitro Cancer Models in Robot‐Assisted Production

Advanced Robotics Research, EarlyView.
An AI‐powered, robot‐assisted framework automatically produces, images, and analyzes 3D tumor spheroids to evaluate drug efficacy. Integrated modules handle spheroid formation, live/dead staining, brightfield imaging, and automated image analysis, including spheroid segmentation, viability and metrics to assess the drug treatment efficacy. The workflow
Dalia Mahdy, Jesus Nieves, Lukas Königer, Matthias Peindl, Fabio Erhard, Marc Möllmann, Anke Klingner, Markus Münig, Bibin Babu, Thomas Schwarz, Marco Metzger, Gudrun Dandekar, Maximiliane Wußmann, Jan Hansmann   +13 more
wiley   +1 more source

JQ1 reduces intracellular lipid in INS-1 cells.

, 2016
(A) Images are of INS-1 cells incubated with indicated concentrations of JQ1 for 3 days and stained with Nile Red. Results are from a single representative experiment repeated 5 times. Lipid droplets appear as bright dots within cells in micrographs (40X
Orian S. Shirihai (256826), Barbara E. Corkey (172722), Jude T. Deeney (335344), Anna C. Belkina (2578606), Gerald V. Denis (575552)   +4 more
core   +1 more source

Ahcy Acts as an Effector of Hnf4a‐Driven Super‐Enhancer Activation to Alleviate MASLD During Intermittent Fasting

Advanced Science, EarlyView.
Our study identifies an Hnf4a‐driven super‐enhancer of hepatic Ahcy that mediates the protective effects of intermittent fasting against MASLD. Disruption of the Ahcy super‐enhancer reduces Ahcy expression and exacerbates lipid accumulation. This pathway prevents aberrant promoter hypermethylation by maintaining the SAM/SAH balance, as exemplified by ...
Huafeng Chen, Shilin Zhang, Xiaojie Deng, Wenqiang Xie, Fen Xu, Jie Shen, Hua Liang   +6 more
wiley   +1 more source

Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation

Advanced Science, EarlyView.
Dynamic supramolecular assembly reshapes targeted protein degradation by coordinating modular degrader construction, delivery, functional integration, and intracellular assembly or activation across proteasomal, endosomal–lysosomal, and autophagy–lysosomal pathways.
Kongjun Liu, Xue Yuan, Yan Zhou, Rui Yuan, Shaocheng Xie, Yong Chen, Peiyi Wang, Jianmei Gao, Qihai Gong   +8 more
wiley   +1 more source

Generalizable Strategies for the Synthesis of Cereblon‐Recruiting PROTAC Prodrugs

Angewandte Chemie, Volume 138, Issue 40, 28 September 2026.
Cereblon‐recruiting PROTACs remain challenging to derivatize for prodrug‐based delivery. In this study, three complementary conjugation strategies enabled the efficient synthesis of cleavable PROTAC prodrugs with tunable release kinetics that can be incorporated into a library of PEGylated constructs and bottlebrush prodrugs.
Aiden X. Wang, Bin Liu, Elise M. Ackerman, Yichen Xiang, Hung V.‐T. Nguyen, Yivan Jiang, Angela N. Koehler, Jeremiah A. Johnson   +7 more
wiley   +2 more sources

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma [PDF]

Molecular Cancer Therapeutics, 2016
Abstract The bromodomain and extra-terminal domain inhibitor JQ1 has marked antitumor activity against several hematologic malignancies as well as solid tumor models. Here, we investigated its activity in vitro and in vivo against models of childhood rhabdomyosarcoma and Ewing sarcoma.
Hemant K, Bid, Doris A, Phelps, Linlin, Xaio, Denis C, Guttridge, Jiayuh, Lin, Cheryl, London, Laurence H, Baker, Xiaokui, Mo, Peter J, Houghton   +8 more
openaire   +2 more sources